大和发布研报称，上调对泰格医药（300347）(03347)的2026至2027年收入预测1%至7%，但下调同期每 股盈利预测8%至12%，因调低毛利率并上调销售、行政开支及研发开支。维持"持有"评级，目标价由 38港元升至45港元。 泰格医药发盈喜，预期2025年收入同比增长1%至16%，至66.6亿至76.8亿元人民币(下同)，在2024年跌 11%后重拾增长。料净利润同比上升105%至204%，至8.3亿至12.3亿元;经常性净利润同比下跌43%至 61%，至3.3亿至4.9亿元，主要由于订单取消、订单单价下降以及团队扩张相关营运成本增加。展望 2026年，该行估计公司收入将同比增长16%至约80亿元，净利润同比增长14%，净利润率同比收窄1个 百分点至15%。 ...

交银国际指出，据统计，2026年前两个月全球XDC赛道共发生25项投融资事件，相比2025年同期的18 项显著增长；XDC候选药物BD交易呈现类似趋势，交易数量保持稳定、合计首付款总额大幅增长。 2024年年初以来，XDC领域投融资事件数、BD交易数和首付款总额呈逐步上升态势。投融资和BD交易 持续活跃，将进一步拉动XDC CRDMO行业下游需求改善，药明合联作为技术实力和一体化交付能力 布局的龙头企业，有望持续受益于这一重要趋势、并扩大市场份额。 消息面上，药明合联此前发布2025年业绩盈喜预告，交银国际表示，基于公司盈利预告，略微下调 2025-27年收入和经调整净利润预测1-3%，至58.8亿/82.8亿/111.1亿元(人民币，下同)、16.0亿/24.5 亿/34.2亿元，分别对应38%/46%2025-27年CAGR，强劲增速主要得益于综合CMC订单的快速增长、尤 其是临床后期/商业化阶段订单贡献的提升。 药明合联(02268)盘中涨超8%，截至发稿，涨6.6%，报62.2港元，成交额2.53亿港元。 ...

据了解，翼帆医药是水滴公司旗下的数字化临床患者招募平台，依托水滴公司庞大的患者群体和数字化 AI能力开展患者招募等业务，聚焦解决临床试验"招募慢、匹配难"的行业痛点，并助力国内外知名药企 提高研发效率。 近日，水滴公司旗下北京翼帆风顺医药科技有限公司自主研发的 "临床药物试验患者智能匹配技术" 正 式获得国家发明专利（专利号：ZL202210080502.4）：临床药物试验患者的匹配方法、装置及计算机设 备。水滴公司此前已经自主研发水滴水守大模型，驱动业务全面提效。此次新的专利技术通过深度神经 网络与自然语言处理技术的创新融合，彻底解决了传统临床药物试验患者招募中 "工作量大、效率低 下、易出错" 的行业痛点，为医药创新研发按下 "加速键"。 财经频道更多独家策划、专家专栏，免费查阅>> 水滴公司是行业内最早布局AI大模型应用的公司之一，每年投入近3亿元用于研发，目前已经积累了 100多项人工智能技术专利。水滴公司此前自主研发的水滴水守大模型，已经成为驱动业务提效的 "中 枢神经"，广泛应用于产品创新、用户服务等众多业务场景，全面提升保险及健康服务全流程的效率和 质量。 责任编辑：钟离 此次推出的智能匹配技术 ...

Market Overview - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.86% to 27,032.54 points, the Hang Seng Tech Index down 1.65% to 5,408.98 points, and the National Enterprises Index decreasing by 1% to 9,175.18 points [1] - Major technology stocks saw a collective drop, including Alibaba down 0.94%, Tencent down 2.28%, and Meituan down 4.5% [1] Sector Performance - Semiconductor stocks surged, with Zhaoyi Innovation rising over 20% and Wallen Technology increasing nearly 10% [1] - AI application stocks saw significant gains, particularly Zhiyuan, which spiked over 41% after the release of its new model GLM-5 [2] - Defensive sectors performed well, with Jiaxin International Resources rising over 4% and achieving a new listing high, while rare earth prices supported the performance of Jinli Permanent Magnet, which rose over 4% [3] Individual Stock Movements - Bole Electric experienced a dramatic increase of over 130%, driven by demand growth in the data center sector [5] - Tigermed Pharmaceutical's stock fell nearly 5% despite a projected net profit increase of 105% for 2025, as its core CRO business showed a decline [5] Analyst Insights - Analysts from CICC noted that the recent market pullback is due to a combination of factors including hawkish Fed expectations and concerns over AI capital expenditure returns [6] - Dongwu Securities suggested a defensive strategy due to reduced trading volume and heightened market caution [6] - Analysts from Guangfa Securities indicated that the Hong Kong market may see a temporary rise following the Lunar New Year, but warned of potential risks post-holiday [6]

Financial Performance - The company expects to report a loss for the fiscal year 2025, with net profit projected to decline by over 50% compared to the previous year [1] - Estimated net profit attributable to shareholders for 2025 is projected to be between -39.85 million and -26.79 million yuan, a decrease of 174.56 million to 187.62 million yuan year-on-year, representing a decline of 118.13% to 126.97% [1] - The net profit after deducting non-recurring gains and losses for 2025 is expected to be between -68.73 million and -45.82 million yuan, a decrease of 171.21 million to 194.12 million yuan year-on-year, reflecting a decline of 136.54% to 154.82% [1] - In 2024, the company achieved operating revenue of 1.142 billion yuan, a year-on-year increase of 9.94%, while net profit attributable to shareholders decreased by 24% to 148 million yuan [1] IPO and Fundraising - The company was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on September 3, 2024, issuing 35.24 million shares at a price of 19.06 yuan per share, representing 25% of the total share capital post-issuance [2] - Total funds raised from the IPO amounted to 671.77 million yuan, with a net amount of 609.65 million yuan after deducting issuance costs, which was 992.36 million yuan less than the original plan [2] - The company intended to raise 1.602 billion yuan for projects including the headquarters and innovation transformation center, a high-quality non-clinical innovative drug comprehensive evaluation platform expansion, and to supplement working capital [2]

Core Viewpoint - Medisi plans to enhance its competitive advantage in preclinical integrated research through continuous development and integration strategies [2] Group 1: Business Strategy - The company aims to deepen its integrated research strategy in preclinical studies [2] - Medisi intends to explore suitable opportunities for expanding its upstream and downstream industry chain based on actual business conditions [2] - The company seeks to align its expansion efforts with its internationalization strategy while strengthening its existing research and development technology platform [2] Group 2: Future Plans - Medisi will supplement or enhance its existing business chain as part of its growth strategy [2] - Any future merger and acquisition plans will be executed in accordance with relevant laws and regulations, ensuring timely decision-making and information disclosure [2]

格隆汇2月9日丨华兰股份(301093.SZ)公布，董事会同意公司全资子公司海南灵擎数智医药科技有限公 司（在本公告里简称"灵擎数智"）与美国Insilicom LLC前首席技术官俞开先先生（CTO）及美国科学院 院士LIU JUN（刘军）先生领衔的技术团队开展合作，即灵擎数智、持股平台1（将由灵擎数智与俞开 先所控制的公司共同出资设立）、持股平台2【将由俞开先所控制的公司与LIU JUN（刘军）共同出资 设立】拟以自有资金共同出资设立一家合资公司。其中，灵擎数智控股合资公司，合资公司将纳入公司 合并报表范围。 合资公司拟聚焦于以知识图谱为核心的药物重定向与药物警戒相关服务，通过整合多源异构数据，为药 物研发与安全管理提供智能化解决方案，具体经营范围以工商登记信息为准。 ...

投资界2月5日消息，近日，湖南君行健创业投资有限公司（简称 "君行健资本"）旗下青岛君行健泰创 业投资基金合伙企业（有限合伙）完成中国证券投资基金业协会备案、青岛追光致远创业投资基金合伙 企业（有限合伙）顺利完成扩募，标志着君行健资本在生物医疗与先进制造两大核心赛道的布局再提 速，管理基金矩阵进一步扩容至 8 支。 自2021年成立以来，君行健资本已构建起 "基金募资 - 项目投资 - 投后赋能 - 退出增值" 的全周期服务体 系，管理资金规模超 6亿元，投资版图覆盖20余家优质企业，其中多家已迈入资本化关键阶段。 此次双基金备案落地，既是君行健资本管理能力的重要印证，更是布局硬科技与大健康赛道的战略升 级：依托已投企业生态，实现"基金 - 项目 - 产业" 联动，为被投企业嫁接供应链、客户与资本市场资 源。立足湖南、辐射全国，重点关注华中、长三角、珠三角等创新高地，兼顾技术先进性与商业化潜 力。以 5-10 年长期视角布局，聚焦能真正解决产业痛点、创造社会价值的创新企业。 君行健泰基金：生物医疗领域的 "价值发现者"。聚焦生物医药、医疗器械、医药研发服务等前沿方 向，深度布局创新诊疗技术与高端医疗器械赛道， ...

Core Viewpoint - Ruizhi Pharmaceutical (300149) expects to achieve a net profit attributable to shareholders of 12.3 million to 18.45 million yuan in 2025, marking a turnaround from losses to profitability [1] Group 1: Financial Performance - The company anticipates a net profit turnaround in 2025 due to the recovery of global innovative drug market demand [1] - The expected net profit range for 2025 is between 12.3 million yuan and 18.45 million yuan [1] Group 2: Operational Strategy - Ruizhi Pharmaceutical is leveraging its full-process R&D platform as a core competitive advantage to enhance market expansion efforts and improve order acquisition capabilities [1] - The company is implementing cost reduction and efficiency enhancement measures, leading to a decrease in period expenses and improved profitability [1] Group 3: Asset Management - In 2024, the company recorded a goodwill impairment loss of 139 million yuan, reducing the related goodwill book value to zero, which means no further goodwill impairment losses are expected in 2025 [1]

利润表现： 归母净利润 8.3 亿 – 12.3 亿元，同比增长 105%-204%，低于瑞银预期（15.0 亿元）和市场一致预期（13.2 亿 元）； 瑞银 – 泰格医药 ：2025 预告收入中值超预期，但利润低于预期 泰格医药公布 2025 年业绩预告，收入中值超预期但利润低于预期，我们基于现金流贴现（DCF）模型维持目标价 72.4 元（加权平均资本成本 8.3%，终期增长率 3%），隐含 2026/2027 年 47 倍 / 36 倍市盈率，维持 "买入"评级。 2025 年业绩预告核心数据 收入表现： 全年收入同比增长 1% 瑞银 – 泰格医药 ：2025 预告收入中值超预期，但利润低于预期 泰格医药公布 2025 年业绩预告，收入中值超预期但利润低于预期，我们基于现金流贴现（DCF）模型维持目标价 72.4 元（加权平均资本成本 8.3%，终期增长率 3%），隐含 2026/2027 年 47 倍 / 36 倍市盈率，维持 "买入"评级。 2025 年业绩预告核心数据 收入表现： 全年收入同比增长 1%-16%，达到 66.6 亿 – 76.8 亿元；隐含第四季度收入增长 6.4%-72.9%，中 ...